Scienture Q2 revenue surges on REZENOPY launch
Scienture Q2 revenue surges on REZENOPY launch
Overview
US specialty pharma firm's Q2 revenue rose sharply, driven by commercial launch of REZENOPY
Q2 gross margin reached 97.7%, reflecting growing commercial revenue base
Net loss for Q2 narrowed 58% yr/yr as operating expenses declined
Outlook
Company expects to accelerate revenue growth in H2 2026 and into 2027
Company aims to achieve profitability in 2027
Company expanding commercial access for Arbli and launching REZENOPY in Q3 2026
Result Drivers
REZENOPY LAUNCH - Co commenced commercial launch of REZENOPY, establishing its second commercial product and expanding its revenue-generating portfolio
ARBLI EXPANSION - Expanded ARBLI payer coverage and commercial access, adding approximately 12.5 million covered lives
EXPENSE MANAGEMENT - Q2 operating expenses decreased approximately 41% yr/yr, demonstrating continued expense management and operating discipline
Company press release: ID:nGNX4D0rjR
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Gross Margin |
| 97.70% |
|
Q2 Operating Expenses |
| $3 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Scienture Holdings Inc is $1.50, about 222.6% above its August 13 closing price of $0.47
Reuters Recommended Reads
Aug 13 - Eton Pharmaceuticals Q2 adjusted EPS beats estimates, revenue up 99% on HEMANGEOL relaunch
Aug 13 - Pelthos Therapeutics Q2 revenue rises on Zelsuvmi adoption
Aug 12 - Omeros Q2 YARTEMLEA net revenue jumps 190%
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)